Skip to main content
  • Notice of Privacy Incident
  • Medicaid Provider Termination Alert: Revalidation deadlines are approaching. Failure by providers to revalidate will lead to termination and payment suspension. Check your account now at https://impact.illinois.gov/ to learn if your required revalidation is due this month. More revalidation information here.

Drugs and Therapeutics (D & T) Committee Meeting Results for: September 14, 2016

Drugs and Therapeutics (D & T) Committee

Meeting Results

September 14, 2016

Drug Name

Review Type

Committee Recommendation

Prior Approval Status – Final Determination

Viekira XR

New Drug Initial Review

Require Prior Approval (Non-Preferred)
Prior Approval Required (Non-Preferred)

Epclusa

New Drug Initial Review
Preferred with a Prior Approval
Preferred with a Prior Approval

Ocaliva

New Drug Initial Review

Require Prior Approval (Non-Preferred)
Prior Approval Required (Non-Preferred)

Briviact

New Drug Initial Review

Require Prior Approval (Non-Preferred)
Prior Approval Required (Non-Preferred)

Xtampza ER

New Drug Initial Review
Require Prior Approval (Non-Preferred)
Prior Approval Required (Non-Preferred)

Adzenys XR-ODT

New Drug Initial Review
Require Prior Approval (Non-Preferred)
Prior Approval Required (Non-Preferred)

Spinosad

New Drug Initial Review
Remove Prior Approval (Preferred)
Prior Approval Removed (Preferred)

Orenitram ER

New Drug Appeal
Require Prior Approval (Non-Preferred)
Prior Approval Required (Non-Preferred)